4/P-signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase 1/2 (Erk) phosphorylation were also studied. RESULTS The number of CD19+ CD24hi CD38hi B cells in patients with AD was similar to that in healthy controls. However, B10 cells were decreased in patients with AD. The proportion of B10 cells was negatively associated with blood basophil counts but not associated with disease activity. CD19+ CD24hi CD38hi B cells from AD patients were more susceptible to apoptosis upon stimulation with CpG, LPS and CD40L. B cells from AD patients showed lower STAT3 and Erk phosphorylation. CONCLUSIONS CD19+ CD24hi CD38hi B cells were unchanged in atopic dermatitis while B10 cells were decreased. The increased B cell apoptosis, decreased STAT3 and Erk phosphorylation might contribute to these changes. This article is protected by copyright. All rights reserved.Cutaneous mucormycosis occurs in immunosuppressed, uncontrolled diabetic, or traumatized patients after skin fungal spores inoculation.1-4 Here, we present a case of an extensive cutaneous mucormycosis complicating the use of an insulin infusion pump. This article is protected by copyright. All rights reserved.BACKGROUND Myocardial infarction (MI) is a high-risk condition especially when filling pressure is raised, and earlier reports have suggested that E/e’ is associated with poor outcome. However, whether E/e’ predicts risk better than LVEF, which is the current standard of practice, is not known. We investigated this question in the largest and most rigorous study of MI patients so far. METHODS AND RESULTS We studied 660 patients with ST-elevation MI (STEMI) treated with primary percutaneous coronary intervention and related E/e’ to short-term mortality (in-hospital death), as well as long-term events at 2 years comprising (a) a composite of MI, stroke, heart failure, and death, and (b) death alone. Short-term models were adjusted for age, sex, and LVEF. Long-term models were adjusted for age, sex, diabetes, revascularization procedure, history of MI, hypertension, renal function, drugs on discharge, and LVEF. Elevated E/e’> 15 indicated higher risk of short-term events (n = 197.0% (95% confidence interval 3.4-10.8%) vs. 1.0% (0.3 – 2.3%); adjusted odds ratio 3.7 (1.3-10.5)). While elevated E/e’ was also associated with long-term outcomes (n = 103 composite events 15.9% (11.9% – 21.4%) vs 6.8% (5.2% – 8.7%), P  less then  .001; n = 38 death events 6.0% (3.9% – 9.5%) vs 2.0% (1.3% – 3.2%), P = .001), E/e’ was rendered nonsignificant for long-term outcomes by multivariable adjustment (p = ns for both). LVEF, on the contrary, was a highly significant predictor in the adjusted long-term model. CONCLUSION E/e’ is associated with poor outcome in STEMI, but LVEF is a stronger predictor of long-term risk. © 2020 The Authors. Echocardiography published by Wiley Periodicals, Inc.OBJECTIVE To evaluate the changes in occlusal surface area (OSA) and occlusal force distribution (OFD) following the wear of Vacuum-Formed (VFR), Hawley (HR) and Bonded (BR) retainers, using T-Scan III. MATERIALS AND METHODS A total of 60 subjects using three different maxillary and mandibular orthodontic retainers, VFR (n20), HR (n20), and BR (n20) were included in this study. The changes in OSA and OFD were evaluated using the T-Scan III. The evaluations were made two hours after debonding orthodontic appliances (T0) and in the 3rd (T1) and 6th (T2) months of the retention phase. CHIR-124 mw RESULTS For left (LDA), right (RDA), and posterior dental arches (PDA), intragroup comparison of OSA showed significant increase in the VFR and HR groups at T1-T2 and T0-T2 time-intervals and in the BR group at T0-T1 and T0-T2 time-intervals. For the anterior dental arch (ADA), only the increase in the HR group at T0-T1 and T0-T2 time-intervals was found significant. When compared between the groups, the changes between HR and BR groups detected at T1-T2 time-interval for the RDA and at T0-T1 and T0-T2 time-intervals for the ADA were found significant. Intragroup comparison of OFD displayed significant changes only in the BR group. At T0-T1 time-interval the decrease in the ADA and the increase in the PDA were found significant. Also, intergroup OFD comparison exhibited significant differences between HR and BR groups at T0-T1 time-interval for ADA and PDA. CONCLUSION Although no significant differences were found between the VFR group, the increase in OSA occured faster in the PDA in the BR group, whereas in the ADA it was significant only in the HR group. This article is protected by copyright. All rights reserved.Japan is now a super-aged society, and the older population is estimated to reach 39.9% in 2060 (Cabinet Office, 2016). Long-term care insurance was launched in 2000 to support the older population in community-settings. Presently, many parents in their 80s who are receiving pensions are supporting their single children in their 50s who have experienced social withdrawal and been unemployed since their youth. This situation, commonly called the ‘8050 issue’, is increasing in Japan (Ministry of Health, Labour, and Welfare, 2019). This article is protected by copyright. All rights reserved.BACKGROUND Letermovir was approved in 2017 for prevention of cytomegalovirus (CMV) infection in seropositive (R+) allogeneic hematopoietic cell transplantation (HCT) patients. Post-marketing data with this new agent are scarce. METHODS We compared the incidence of both CMV reactivation (any viremia) and clinically significant CMV infection (CS-CMVi; CMV DNAemia leading to preemptive treatment or presence of CMV tissue invasive disease) at days +100 and +200 post-HCT in 25 adult allogeneic HCT patients who received letermovir prophylaxis (until day 100) and a historical control group of 106 CMV R+ allogeneic HCT recipients who underwent CMV preemptive therapy. RESULTS CMV reactivation within 100 days post-HCT was lower in the letermovir group vs control group (20% vs 72% respectively, P  less then  .001). The 100-day cumulative incidence of CS-CMVi was significantly lower in the letermovir group vs control group (4% vs 59% respectively, P  less then  .001). Significantly reduced incidence of CMV reactivation and CS-CMVi was also observed at 200 days in the letermovir group.